Skip to main content
logo
Wuhan YZY Biopharma Co., Ltd. (HKG:2496)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.690
-0.110 (-2.89%)
Jun 24, 2026, 9:44 AM HKT

Wuhan YZY Biopharma Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
66.8666.86107.81-2.2812.16
Revenue Growth
-55.23%-37.99%---81.28%-
Gross Profit
10.7410.7485.07-2.2812.16
Operating Income
-80.56-80.56-97.98-165.4-175.58-132.23
Net Income
-84.73-84.73-97.6-191.7-188.87-148.52
Earnings Per Share
-0.44-0.44-0.50-1.04-1.10-0.98
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
100.07100.07126.28196.68168.5285.59
Total Debt
127.76127.76127.3590.1176.6728.48
Net Cash (Debt)
-27.69-27.69-1.08106.5791.8557.11
Net Cash Growth
---16.02%60.85%-
Net Cash Per Share
-0.14-0.14-0.010.580.530.38

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-21.58-21.58-100.72-186.02-176.7-98.71
Capital Expenditures
-0.89-0.89-1.51-1.93-1.41-1.9
Free Cash Flow
-22.46-22.46-102.22-187.95-178.11-100.61
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
16.06%16.06%78.90%-100.00%100.00%
Operating Margin
-120.50%-120.50%-90.88%--7710.89%-1087.03%
Pretax Margin
-126.73%-126.73%-90.53%--8294.51%-1220.96%
Profit Margin
-126.73%-126.73%-90.53%--8294.51%-1220.96%
FCF Margin
-33.60%-33.60%-94.81%--7822.31%-827.14%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
9.6120.9013.99---